OncoMatch/Clinical Trials/NCT07101705
An Open-label, Single-arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of OriV508 Injection in Treating Relapsed/Refractory Hematological Malignancies
Is NCT07101705 recruiting? Yes, currently enrolling (Sep 2026). This Early Phase 1 trial studies OriV508 for multiple myeloma (mm).
Treatment: OriV508 — This is a single center, single arm, open-label, dose escalation, phase 1 study to evaluate the safety, tolerability, preliminary efficacy and immunogenicity of OriV508 injection for patients with relapsed/refractory hematological malignancies.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Multiple Myeloma
Non-Hodgkin Lymphoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: anti-tumor therapy — Multiple Myeloma
For MM subjects only: Have received at least 2 lines of anti-tumor therapy, with each line of therapy undergoing at least one complete treatment cycle, and have experienced disease progression during or within 12 months after the last treatment; or be judged by the investigator as double-refractory to immunomodulators and proteasome inhibitors, and did not achieve a minimal response (MR) or better during the last treatment or experienced disease progression within 60 days after the end of treatment.
Must have received: anti-tumor therapy — aggressive B-NHL
For aggressive B-NHL subjects only: Have received at least 2 lines of anti-tumor therapy, and are refractory to the last line of therapy (at least 2 cycles) (best response is PD or SD) or have experienced disease progression after the end of treatment. Previous treatments must include standard treatment regimens with anti-CD20 monoclonal antibodies (except for subjects with CD20-negative tumors) and anthracyclines
Cannot have received: organ transplantation
Received organ transplantation
Cannot have received: allogeneic hematopoietic stem cell transplantation
Received...allogeneic hematopoietic stem cell transplantation
Cannot have received: vesicular stomatitis virus G (VSVG)-pseudotyped viral therapy
Previously treated with any viral therapy using vesicular stomatitis virus G (VSVG)-pseudotyped virus
Lab requirements
Blood counts
Hemoglobin ≥ 6 g/dL (no RBC transfusion within 1 week prior to screening, recombinant human erythropoietin permitted); ANC ≥ 750 /μL (no G-CSF within 1 week or peg-G-CSF within 2 weeks prior to screening); Platelet count ≥ 50,000 /μL; Lymphocyte count ≥ 500 /μL
Kidney function
eGFR (MDRD equation) ≥ 40 mL/min/1.73m2 (MM subjects with eGFR < 40 mL/min/1.73m2 may be enrolled at investigator discretion)
Liver function
ALT and AST ≤ 3.0 × ULN, total bilirubin ≤ 1.5 × ULN (for subjects with Gilbert's syndrome or liver invasion by tumor, ALT and AST ≤ 5.0 × ULN and total bilirubin ≤ 3 × ULN are permitted)
Cardiac function
Left ventricular ejection fraction ≥ 45%
Hemogram, renal, liver, and cardiac function requirements as detailed in inclusion criteria
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07101705 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior organ transplantation, allogeneic hematopoietic stem cell transplantation, vesicular stomatitis virus G (VSVG)-pseudotyped viral therapy disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages